Next |
home / stock / nktx / nktx message board
Subject | By | Source | When |
---|---|---|---|
Turns out the trial in solid tumours (ccRCC, | jondoeuk | investorshub | 04/26/2023 2:17:08 AM |
(OT) Dr. Rezvani presented some early, but impressive | jondoeuk | investorshub | 04/25/2023 8:44:27 PM |
Updated results from the ongoing trial of NKX101 | jondoeuk | investorshub | 04/01/2023 8:35:01 PM |
ADAM17 knockout NK or CAR NK cells augment | jondoeuk | investorshub | 03/15/2023 2:00:46 AM |
Watching from the sidelines, but the NKX101 delayed | jondoeuk | investorshub | 02/13/2023 2:50:22 AM |
NKX019 update https://www.globenewswire.com/news-release/2022/12/05/2567250/0/en | jondoeuk | investorshub | 12/06/2022 1:15:23 AM |
Posters | jondoeuk | investorshub | 12/06/2022 1:11:55 AM |
SITC titles | jondoeuk | investorshub | 10/05/2022 8:06:20 PM |
Additional NKX101 and NKX019 clinical data expected by | jondoeuk | investorshub | 08/11/2022 9:53:52 PM |
Cowen 3rd Annual Oncology Innovation Summit webcast https://wsw.com/webcast/cowe | jondoeuk | investorshub | 06/26/2022 5:05:01 PM |
Time for some momo/fomo to kick in. Let's | crudeoil24 | investorshub | 04/29/2022 5:50:01 PM |
Offering is now closed Company raised over | crudeoil24 | investorshub | 04/29/2022 1:30:55 PM |
20$ | stock1ace1 | investorshub | 04/28/2022 2:30:26 PM |
$NKTX is a great $$$$$ opportunity. | crudeoil24 | investorshub | 04/27/2022 6:37:20 PM |
Not a p&d. Some folks need to learn | crudeoil24 | investorshub | 04/27/2022 4:48:33 PM |
18.93 > > Looks like $NKTX | crudeoil24 | investorshub | 04/27/2022 4:40:39 PM |
Front Loaded Pump and Dump, They are trying | Saving Grace | investorshub | 04/27/2022 4:26:16 PM |
That would be if the number 15 was | JamBop | investorshub | 04/26/2022 12:41:51 PM |
Shouldn't this open at $15 when the market | Gator44 | investorshub | 04/26/2022 12:00:00 PM |
znewcar1: NKTX 141% v109M C18.72 f33M H18.95 gapN held yet choppy | znewcar1 | investorshangout | 04/26/2022 1:08:28 AM |
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing...
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of systemic sclerosis, myositis and vasculitis Clinical data ...